The summary is generally fair and captures both sides. That said, it's important to keep the company's stage in mind. AbCellera is still an early-stage biotech, yet it is already generating meaningful collaboration revenue while advancing its own pipeline. For a company at this stage, partnership quality, clinical progress, and future contracted revenue can be just as important as quarter-to-quarter GAAP results.